Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.79 |
| ▸ | RAB9A | P51151 | 8/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.79 |
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.60 |
| ▸ | KDM1A | O60341 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11433155 | 0.92 | NPC1 (0.93) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL442845 | 0.92 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL443732 | 0.91 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL10495055 | 0.89 | NPC1 (0.82) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL11424416 | 0.89 | NPC1 (0.93) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL1578277 | 0.89 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL4257390 | 0.89 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL29462107 | 0.88 | HDAC1 (0.64) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL444832 | 0.88 | HDAC1 (0.64) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL8268336 | 0.87 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120197417-A | Method for calculating clearance of radial bearing at lower part of main pump | 江苏核电有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-221343663-U | Bridge crane double-lifting hook synchronous detection system | 华能澜沧江水电股份有限公司 | 2024-07-16 | — | — | CN | claimed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-12492388-B2 | Materials and methods for treatment of hemoglobinopathies | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-09 | — | — | US | disclosed |
| CN-120197417-A | Method for calculating clearance of radial bearing at lower part of main pump | 江苏核电有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-120197417-A | Method for calculating clearance of radial bearing at lower part of main pump | 江苏核电有限公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025055194-A1 | GENETICALLY ENGINEERED BACTERIUM FOR DE NOVO SYNTHESIS OF VANILLIN USING GLUCOSE AS SUBSTRATE, AND USE THEREOF | 北京化工大学 | 2025-03-20 | — | — | WO | disclosed |
| EP-4524234-A1 | GENETICALLY ENGINEERED BACTERIUM USING GLUCOSE AS SUBSTRATE FOR DE NOVO SYNTHESIS OF VANILLIN AND APPLICATION THEREOF | Beijing University Of Chemical Technology (CN) | 2025-03-19 | — | — | EP | disclosed |
| CN-119361160-A | Expert rule-based low-molecular heparin accurate drug delivery decision system and method | 吉林大学第一医院 | 2025-01-24 | — | — | CN | disclosed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | NPC1 1614/4885RAB9A 4162/4885SMN1; SMN2 3363/4885 |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AADAC, HDAC3, HDAC4 | NPC1 965/4885RAB9A 4653/4885SMN1; SMN2 4389/4885 |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | NPC1 1924/4885RAB9A 4301/4885SMN1; SMN2 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.